Ministry of Health and Welfare Launches Pilot Project for Expedited Listing
Public Recruitment of Participating Companies and Drugs Open Until August 31

The Ministry of Health and Welfare will launch a pilot project to expedite the listing of rare disease treatments on the national health insurance, aiming to reduce the current maximum review period from 240 days to within 100 days.


Rare Disease Treatments to Be Listed on National Health Insurance Within 100 Days View original image

On June 30, the ministry announced that it will publicly recruit pharmaceutical companies and eligible drugs to participate in the "Pilot Project for Expedited Listing of Rare Disease Treatments" from July 1 to August 31.


This project is designed to significantly streamline the existing national health insurance listing procedures so that treatments developed for rare diseases—where patient populations are small and short-term verification of treatment efficacy is challenging—can be made available to patients earlier.


Previously, cost-effectiveness assessments were conducted before listing on health insurance. Under the pilot, these will shift to a post-listing evaluation model, based on real-world clinical outcomes. Additionally, drug prices and total expenditure negotiations will apply pre-set contract terms. Through these measures, the project aims to reduce the health insurance listing period for rare disease treatments from the current 240 days to a maximum of 100 days.


Drug pricing contracts will guarantee a level equivalent to 90% of the lowest adjusted price among the so-called "A8 countries": the United States, United Kingdom, Germany, France, Italy, Switzerland, Japan, and Canada. The projected claim amount will be initially set within a maximum limit of 30 billion won, based on the amount proposed by the pharmaceutical company, and will be adjusted afterward according to actual usage.


Eligible participants in the pilot are treatments for diseases designated as rare diseases under the special exemption program, that are either currently undergoing approval review or have already been approved in Korea. In addition, the drugs must be reimbursed and have confirmed pricing in at least three of the A8 countries.


The government will comprehensively evaluate the submitted drugs based on the availability of alternative treatments, disease severity, impact on the national health insurance budget, and plans to ensure stable treatment for patients, selecting up to five products for the pilot.


Pharmaceutical companies wishing to participate must submit an application form, drug-related materials, and a post-listing evaluation plan to the Health Insurance Review and Assessment Service by 6:00 p.m. on August 31. The Ministry of Health and Welfare will announce the final selection results in September after a review process.



Kwon Byungki, Director of National Health Insurance Policy at the Ministry of Health and Welfare, stated, "This measure is intended to significantly shorten the listing period for rare disease treatments so that patients can access therapies earlier. It is meaningful in that it reflects the longstanding demands of patients with rare diseases."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing